5 research outputs found
Band selection in spectral imaging for non-invasive melanoma diagnosis
A method consisting of the combination of the Synthetic Minority Over-Sampling TEchnique (SMOTE) and the Sequential Forward Floating Selection (SFFS) technique is used to do band selection in a highly imbalanced, small size, two-class multispectral dataset of melanoma and non-melanoma lesions. The aim is to improve classification rate and help to identify those spectral bands that have a more important role in melanoma detection. All the processing steps were designed taking into account the low number of samples in the dataset, situation that is quite common in medical cases. The training/test sets are built using a Leave-One-Out strategy. SMOTE is applied in order to deal with the imbalance problem, together with the Qualified Majority Voting scheme (QMV). Support Vector Machines (SVM) is the classification method applied over each balanced set. Results indicate that all melanoma lesions are correctly classified, using a low number of bands, reaching 100% sensitivity and 72% specificity when considering nine (out of a total of 55) spectral bands
Implementation of an intraoperative electron radiotherapy in vivo dosimetry program
Background:
Intraoperative electron radiotherapy (IOERT) is a highly selective radiotherapy technique which aims
to treat restricted anatomic volumes during oncological surgery and is now the subject of intense re-evaluation. In
vivo dosimetry has been recommended for IOERT and has been identified as a risk-reduction intervention in the
context of an IOERT risk analysis. Despite reports of fruitful experiences, information about in vivo dosimetry in
intraoperative radiotherapy is somewhat scarce. Therefore, the aim of this paper is to report our experience in
developing a program of in vivo dosimetry for IOERT, from both multidisciplinary and practical approaches, in a
consistent patient series. We also report several current weaknesses.
Methods:
Reinforced TN-502RDM-H mobile metal oxide semico
nductor field effect tran
sistors (MOSFETs) and
Gafchromic MD-55-2 films were used as a redundant in vivo treatment verification system with an Elekta
Precise fixed linear accelerator for calibrations and tre
atments. In vivo dosimetry was performed in 45 patients
in cases involving primary tumors or relapses. The m
ost frequent primary tumors were breast (37 %) and
colorectal (29 %), and local recurrences among relapses was 83 %. We made 50 attempts to measure with
MOSFETs and 48 attempts to measure with films in th
e treatment zones. The surgical team placed both
detectors with supervision from the radiation oncologist and following their instructions.
Results:
The program was considered an overall success by the different professionals involved. The absorbed doses
measured with MOSFETs and films were 93.8 ± 6.7 % and 97.9 ± 9.0 % (mean ±
SD
) respectively using a scale in which
90 % is the prescribed dose and 100 % is the maximum absorbed dose delivered by the beam. However, in 10 % of
cases we experienced dosimetric problems due to detector misalignment, a situation which might be avoided with
additional checks. The useful MOSFET lifetime length and the film sterilization procedure should also be controlled.
Conclusions:
It is feasible to establish an in vivo dosimetry program for a wide set of locations treated with
IOERT using a multidisciplinary approach according to the skills of the professionals present and the detectors
used; oncological surgeons
’
commitment is key to success in this context. Films are more unstable and show
higher uncertainty than MOSFETs but are cheaper and
are useful and convenient if real-time treatment
monitoring is not necessary.This work was supported by grants IPT-300000-2010-3 and PI11/01659 from
the Spanish Government and ERDF funds
Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report
<p>Abstract</p> <p>Background</p> <p>Melanoma of the anal region is a very uncommon disease, accounting for only 0.2-0.3% of all melanoma cases. Mutations of the <it>BRAF </it>gene are usually absent in melanomas occurring in this region as well as in other sun-protected regions. The development of a tumour in a longstanding perianal fistula is also extremely rare. More frequent is the case of a tumour presenting as a fistula, that is, the fistula being a consequence of the cancerous process, although we have found only two cases of fistula-generating melanomas reported in the literature.</p> <p>Case Presentation</p> <p>Here we report the case of a 38-year-old male who presented with a perianal fistula of four years of evolution. Histopathological examination of the fistulous tract confirmed the presence of malignant melanoma. Due to the small size and the central location of the melanoma inside the fistulous tract, we believe the melanoma reported here developed in the epithelium of the fistula once the latter was already formed. Resected sentinel lymph nodes were negative and the patient, after going through a wide local excision, remains disease-free nine years after diagnosis. DNA obtained from melanoma tissue was analysed by automated direct sequencing and the <it>V600E </it>(<it>T1799A</it>) mutation was detected in exon 15 of the <it>BRAF </it>gene.</p> <p>Conclusion</p> <p>Since fistulae experience persistent inflammation, the fact that this melanoma harbours a <it>BRAF </it>mutation strengthens the view that oxidative stress caused by inflammatory processes plays an important role in the genesis of <it>BRAF </it>gene mutations.</p
GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m2 (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However, several methodological flaws have been identified in PRODIGE 7, specially the HIPEC protocol or the choice of overall survival as the main endpoint, so its results have not been assumed as definitive, emphasizing the need for further research on HIPEC. It seems that the HIPEC protocol with high-dose mytomicin-C (35 mg/m2) is the preferred regime to evaluate in future clinical studies. GECOP-MMC is a prospective, open-label, randomized, multicenter phase IV clinical trial that aims to evaluate the effectiveness of HIPEC with high-dose mytomicin-C in preventing the development of peritoneal recurrence in patients with limited peritoneal metastasis from colon cancer (not rectal), after complete surgical cytoreduction. This study will be performed in 31 Spanish HIPEC centres, starting in March 2022. Additional international recruiting centres are under consideration. Two hundred sixteen patients with PCI ≤ 20, in which complete cytoreduction (CCS 0) has been obtained, will be randomized intraoperatively to arm 1 (with HIPEC) or arm 2 (without HIPEC). We will stratified randomization by surgical PCI (1-10; 11-15; 16-20). Patients in both arms will be treated with personalized systemic chemotherapy. Primary endpoint is peritoneal recurrence-free survival at 3 years. An ancillary study will evaluate the correlation between surgical and pathological PCI, comparing their respective prognostic values. HIPEC with high-dose mytomicin-C, in patients with limited (PCI ≤ 20) and completely resected (CCS 0) peritoneal metastases, is assumed to reduce the expected risk of peritoneal recurrence from 50 to 30% at 3 years. EudraCT number: 2019-004679-37; Clinicaltrials.gov: NCT05250648 (registration date 02/22/2022, )